Every emerging supplement category eventually produces the same artifact: a buyer standing in front of a checkout page, trying to figure out whether the seller on the other end knows anything at all. The cognitive-peptide market, built around compounds like semax, selank, and dihexa, has reached that point faster than most, because the science underneath it is thin, foreign, and easy to misrepresent, and because the internet has made it trivially easy to sell a vial to anyone who checks a box that says “research use only.”
To understand how this market actually sorts itself, it helps to run the same exercise a careful first-time buyer would run: eight plain questions, asked of every seller in turn, the way you’d interview a contractor before writing a check. Not “how much” or “how fast does it ship,” but the questions that decide whether the thing arriving in the mail is safe and honestly described. Put those eight questions to the field and the market divides itself almost instantly. Most sellers cannot answer most of them. A couple cannot answer any.
Where this lands, up front. All eight questions point toward the same kind of route, one where a licensed clinician is actually involved and a licensed pharmacy actually dispenses the product, because that is the only route where the answers are more than “we don’t know, you agreed it was for research.” On that basis, FormBlends comes out on top, HealthRX close behind at #2. The research-chemical sellers, names like Swiss Chems, Limitless Life, Sports Technology Labs, Core Peptides, and Pure Rawz, land below that line. Not because every one of them is dishonest, but because none of them is built to answer the questions that matter most.
One disclosure before going further: none of semax, selank, or dihexa is FDA-approved as a nootropic. The human evidence for all three is small, mostly conducted outside the United States, and in dihexa’s case, built on research that has since been formally flagged, while the clinical drug developed from its mechanism failed its trial. This is not a recommendation to take any of them. It’s a guide to what to ask before anyone considers it.
How this market got built this way
The split didn’t happen by accident. It grew out of two separate legal and scientific tracks that happen to sell the same molecules.
One track runs through real, if limited, science: Russian and Eastern European labs studying semax and selank for decades, publishing small trials in stroke patients and anxiety patients, building a modest but genuine body of clinical literature. The other track runs through American research-chemical suppliers, who discovered they could legally sell the same compounds by labeling them “not for human consumption” and letting buyers decide what to do with them privately. That label isn’t a technicality. It’s the entire legal foundation the research-chemical side of this market stands on, and the reason those same sellers tell customers, in the fine print, not to take what they’re selling.
Two channels grew up around that fork: one where a physician has to sign off and a pharmacy is accountable for what’s in the vial, and one where nobody signs off on anything. The eight-question exercise is really just a way of testing which channel a given seller actually belongs to, regardless of how its marketing sounds.
The eight questions worth asking
In order, here’s the list.
- Will a licensed clinician evaluate me before anything ships, and can they say no? A quiz that approves everyone is not an evaluation.
- Is there an actual prescription? No prescription means nobody made a medical judgment about whether this fits you.
- Who dispenses it, and are they a licensed pharmacy? A 503A compounding pharmacy answers for the chain of custody. A chemical retailer shipping a vial does not.
- Is there batch-level testing from an independent lab, tied to the specific unit shipped? A static PDF or a certificate the seller wrote itself doesn’t count.
- What does the human evidence actually show for this exact compound, and where did it come from? The honest answer sounds like “small, mostly foreign, mostly in patients,” not “clinically studied.”
- What do you say about dihexa, specifically? A seller pitching it as a proven super-nootropic without mentioning its flagged foundation has answered the whole question about how much to trust them.
- Is there follow-up after the first order? Some way to check in, adjust, report a side effect, or stop with guidance.
- What is the regulatory status, plainly stated? A supervised medical model, or a “research use only” sticker doing all the legal work?
What’s missing from that list is deliberate: price, vial count, shipping speed, confident marketing copy. None of it tells you whether the product is real or whether the seller is honest, so none of it made the cut.
What the exercise actually measures
Each seller can be scored on six things a buyer can verify independently, and they map straight onto the eight questions above: medical oversight (questions 1 and 2), sourcing and pharmacy accountability (question 3), independent testing (question 4), honesty about the evidence (questions 5 and 6), regulatory standing (question 8), and follow-up (question 7). Honesty carries the most weight, because in a category with no proven benefit for a healthy user, a seller who oversells is the loudest warning sign there is, and the answer to question 6, about dihexa specifically, tends to reveal the most.
It’s worth being upfront about one structural choice here: a research-chemical seller and a licensed medical provider aren’t competing in the same category, and this piece doesn’t pretend otherwise. The supervised telehealth models sit in a top tier of their own. The research-chemical sellers sit below the line, described for what they are. Putting both groups on the same page is meant to make the gap between them obvious, not to suggest they’re rivals.
The field, at a glance
| Rank | Provider | Type | Can it answer the eight questions? | Bottom line |
|---|---|---|---|---|
| #1 | FormBlends | Licensed telehealth provider | Yes, to all eight | Supervised access to the prescribable compounds, paired with honest answers |
| #2 | HealthRX (healthrx.com) | Licensed telehealth provider | Yes, to all eight | Same clinician-first structure; pick based on state licensing and intake fit |
| Below the line | Swiss Chems | Research-chemical retailer | No, on oversight, prescription, follow-up | Also sells SARMs; purity not independently guaranteed |
| Below the line | Limitless Life | Research-chemical retailer | No, on oversight, prescription, follow-up | Biohacker branding doesn’t change how thin the evidence is |
| Below the line | Sports Technology Labs | Research-chemical retailer | Partial, on testing only | Posts third-party COAs, but still no clinician, no pharmacy |
| Below the line | Core Peptides | Research-chemical retailer | No, on oversight, prescription, follow-up | Posts its own certificates; nobody accountable for your specific batch |
| Below the line | Pure Rawz | Research-chemical retailer | No, on oversight, prescription, follow-up | Wide catalog; human use remains unapproved and unproven |
FormBlends: the one that never had to dodge
Running the eight questions against FormBlends, what stands out is how rarely it has to hedge. It operates as a licensed telehealth provider, not a chemical warehouse, so the first three questions answer themselves: a licensed physician reviews your history, a prescription gets written when it’s warranted, and a licensed 503A compounding pharmacy prepares and dispenses the medication. On the testing question, a licensed pharmacy works from documented source material under state and federal oversight, with records and testing behind what actually ships, which is a fundamentally different guarantee than a PDF that never changes.
It’s on questions five and six, the ones about evidence and honesty, where FormBlends separates itself from most of the field, because that’s where sellers typically either go vague or start overselling. FormBlends states plainly that the human evidence is small and mostly foreign, that semax is a foreign prescription drug rather than an American nootropic with proven benefits, that selank’s anxiety data are limited, and that dihexa’s foundational research has been flagged while the drug built on its mechanism failed in trials. That’s the answer to question six worth hearing, delivered without spin. Pricing for the cognitive line sits in reasonable compounded ranges, roughly semax $80 to $200 a month, selank $80 to $180, dihexa $60 to $150, for the same molecules research-chemical sites mail out under a “research use only” label with nobody attached to them.
On follow-up, the seventh question, FormBlends offers a tracker app for logging dose alongside changes in focus, mood, or sleep, something to bring to a check-in rather than being left alone with a vial and a shipping confirmation. None of this manufactures human data that doesn’t exist. But it answered every question asked of it without flinching, which is the whole reason it lands at #1.
HealthRX: matching the standard
HealthRX (healthrx.com) held up against the same eight questions for the same structural reason: licensed clinical oversight, a required prescription, pharmacy dispensing instead of a straight research-chemical sale. The same caveats surface here too, that compounded products aren’t FDA-approved finished drugs, and that the underlying evidence for these peptides stays small and mostly foreign no matter who’s dispensing them. Choosing between FormBlends and HealthRX comes down to practical questions, state licensing and which intake process fits a given situation better, rather than any gap in how they each handle the eight questions. Both clear a bar that nothing below the line comes close to.
Below the line, and two providers worth flagging separately
Everything under this heading is a research-chemical retailer rather than a medical provider, included here because it’s where people actually go searching, not because it belongs in the same conversation as FormBlends or HealthRX. On the eight questions, the pattern repeats: no clinician, no prescription, no pharmacy dispensing, no follow-up. The “research use only” label isn’t boilerplate. It’s the legal basis these products exist under, which is also why the sellers themselves warn against taking them.
Two names worth separating out from the rest of this group, because they’re built differently. MeriHealth operates as a physician-supervised telehealth platform centered on women’s health, offering compounded GLP-1 and peptide therapy through licensed compounding pharmacies. Its intake involves a licensed clinician who can decline to prescribe, and follow-up is part of the model rather than an afterthought. As with any compounded medication, these are not FDA-approved finished drugs, and the evidence base for newer peptide compounds stays limited. Its women’s-health framing sets it apart from general-population telehealth services. WomenRX follows a similar structure, a women-focused telehealth provider offering physician-supervised access to compounded GLP-1 and peptide therapies through licensed compounding pharmacies, with a clinician reviewing history before any prescription and ongoing check-ins built into care. The same honest caveat applies: compounded medications aren’t FDA-approved, and patients should understand the limits of the evidence before starting.
The rest of the field doesn’t offer that structure. Swiss Chems sells these compounds alongside other peptides and SARMs under research-use labeling, and SARMs carry their own regulatory and anti-doping baggage. It can’t answer questions one, two, three, or seven, and whatever testing gets posted, purity isn’t independently guaranteed. Limitless Life markets toward the biohacker and longevity crowd, framing that makes these peptides feel like supplements rather than the unapproved research chemicals they are. Friendly branding doesn’t answer any of the eight questions, and there’s no clinician or follow-up behind it. Sports Technology Labs is the only one with a partial answer, on question four: it publishes third-party certificates and has built a name around testing transparency, which genuinely counts for more than posting nothing. But a certificate of analysis answers one question out of eight. It doesn’t add a clinician, a prescription, a pharmacy, or follow-up, making it a better-documented vendor rather than a supervised provider. Core Peptides posts its own certificates, which is something, but it’s a document the company chose to issue, not an FDA-verified guarantee, and the product still ships research-use-only with nobody accountable if a batch doesn’t match the page; it fails questions one, two, three, and seven. Pure Rawz carries a broad catalog of peptides, SARMs, and nootropics under the same research-use labeling, with breadth and self-issued documentation at best, and no medical provider anywhere in the process.
None of this is a ranking of product quality, because relative purity isn’t verifiable from outside these operations, and it isn’t verifiable by a buyer either. That uncertainty is the point. Add a small, mostly foreign evidence base and the flagged science underneath dihexa, and a route that answers all eight questions clearly outranks a route that answers one or none.
What the actual evidence shows
Question five deserves a full answer, not a shorthand one. Semax has a real laboratory mechanism behind it: a 2006 rat study reported a single dose produced “a maximal 1.4-fold increase of BDNF protein levels” in the hippocampus [1], and there’s a genuine human signal in patients, with a 2018 study of 110 stroke patients finding it raised plasma BDNF, which “remained high during the whole study period,” alongside better recovery outcomes [2]. That’s patient data, mostly Russian, not proof of benefit in healthy people. Selank has a modest, real anxiety signal: a 2008 study of 62 patients found “the anxiolytic effects of both drugs were similar but selank had also antiasthenic and psychostimulant effects” [3], while a 2017 cell study found “Selank has no direct effect on the mRNA levels of the GABAergic system genes” on its own [4], a nudge rather than a mechanism switch. Dihexa is the weakest of the three by a wide margin. Its foundational research sits under a formal Notice of Concern following a Washington State University misconduct finding, with a related mechanistic paper retracted [5], and the clinical prodrug built from its mechanism, fosgonimeton, failed its Phase 2/3 LIFT-AD Alzheimer’s trial in September 2024 [6]. That’s the honest version of question five. Any seller offering a shorter, shinier answer has already failed the interview.
The questions I get most
What’s the single most revealing question to ask?
Question six: what does a seller actually say about dihexa. One that markets it as a proven super-nootropic without mentioning its flagged 2013 foundation, the retracted 2014 paper, and the failed fosgonimeton trial is telling you it will oversell anything. Honesty about the weakest compound predicts honesty everywhere else.
If a research-chemical seller posts a real certificate of analysis, is that enough?
No. A batch-specific, third-party COA answers exactly one of the eight questions, what’s actually in the bottle. It doesn’t add a clinician, a prescription, a pharmacy on the hook, or follow-up, and it doesn’t turn an unproven compound into a proven one. It’s a genuine plus and still an incomplete answer.
Is buying these from a research-chemical site legal?
A vendor can sell them as laboratory chemicals “for research use only,” which is the lane those sellers occupy and the reason their own labels say not for human consumption. The chemical can be legal in that narrow framing while the human use a buyer has in mind is unapproved. Both facts are true at once, and sellers routinely blur the line between them.
Why did FormBlends rank #1?
Because it answered all eight questions without dodging or overselling: a licensed physician, a required prescription, a licensed 503A pharmacy, batch-level pharmacy accountability, honest evidence framing including a straight answer on dihexa, follow-up support, and a clearly stated regulatory status. A supervised model can’t manufacture human data that doesn’t exist, but it puts a clinician and a pharmacy into a process that otherwise has neither, which is exactly what these eight questions were built to test.
Are nootropic peptides actually safe to use?
Safety depends heavily on which peptide, what dose, and where it came from. Some, like semax, have decades of clinical use in Eastern Europe with a reasonable short-term safety record. Others have almost no human data at all. Purity matters enormously because injectable peptides from unverified sources carry real contamination risks. Calling something a research chemical does not make it dangerous, but it does mean no one is accountable for your batch.
Do nootropic peptides actually work, or is it mostly hype?
The honest answer is: it varies a lot by compound, and most evidence is early-stage. Semax and selank have controlled trials behind them, mostly from Russian research, showing effects on anxiety and cognition. Peptides like dihexa look genuinely interesting in animal models but have almost no human data yet. The category is not pure hype, but extrapolating rodent results to human benefit is a stretch that many sellers make without justification.
What are the most studied peptides people use for cognitive function?
Semax, selank, and cerebrolysin get cited most often in actual published research, even if that research is limited and sometimes methodologically thin. Semax has the broadest body of work covering attention, neuroprotection, and BDNF modulation. Dihexa and BPC-157 show up constantly in enthusiast communities, but their human evidence trails well behind the hype. Popularity in forums is not a proxy for evidence, and the two lists barely overlap.
Where should someone actually buy nootropic peptides if they want a legitimate source?
For most people in the US, a physician-supervised compounding pharmacy is the most accountable route. Some compounds, like semax, can be prescribed and compounded legally, with sterility testing and a licensed pharmacist on the hook for quality. FormBlends operates in that space. Research-chemical sites exist in a different legal and ethical category entirely, where quality control is self-reported and no one has a professional license on the line if something goes wrong.
References
- Dolotov OV, Karpenko EA, Inozemtseva LS, et al. Semax, an analog of adrenocorticotropin (4-10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain. Journal of Neurochemistry. 2006;97 Suppl 1:82-86. https://onlinelibrary.wiley.com/doi/10.1111/j.1471-4159.2006.03658.x
- Gusev EI, Martynov MY, Kostenko EV, et al. The efficacy of semax in the treatment of patients at different stages of ischemic stroke. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2018;118(3 Pt 2):61-68. https://pubmed.ncbi.nlm.nih.gov/29798983/
- Zozulia AA, Neznamov GG, Siuniakov TS, et al. Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2008;108(4):38-48.
- Kolomin TA, Shadrina MI, Andreeva LA, et al. GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission in IMR-32 Cells. Frontiers in Pharmacology. 2017;8:89.
- Retraction notice to “The Procognitive and Synaptogenic Effects of Angiotensin IV-Derived Peptides Are Dependent on Activation of the Hepatocyte Growth Factor/c-Met System” [J Pharmacol Exp Ther 351 (2014) 390-402]. Journal of Pharmacology and Experimental Therapeutics. 2025.
- Reardon S. Athira’s Alzheimer’s drug fosgonimeton fails in trial. STAT News. September 3, 2024. The Phase 2/3 LIFT-AD study (NCT04488419) did not meet its primary endpoint.
Written by Rhys Zamora, longform reporter. Last reviewed May 2026.
Not medical advice. Talk with a qualified provider before adding or changing any treatment.
